BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Breaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeks
  • Brain maze

    Brain path could relieve pain as an alternative to opioids without producing dependence

    Scientists at the University of Chicago have discovered a signaling pathway guided by nicotinic acetylcholine receptors (nAChRs) that could relieve pain even when tolerance to opioids was present. This mechanism did not produce dependence after treatment and could be explored to develop new drugs.
  • New Celexor Bio to focus on cell depletion of pathologic cells in autoimmune and inflammatory disorders

  • Epitope editing in hematopoietic cells provides CAR T immunotherapy against all types of blood cancer

  • Replay’s Syena and Jura Bio collaborate to advance TCR-NK therapies for cancer

  • Seinda Pharmaceutical patents new peptides for ocular conditions

  • Brain path could relieve pain as an alternative to opioids without producing dependence

    Scientists at the University of Chicago have discovered a signaling pathway guided by nicotinic acetylcholine receptors (nAChRs) that could relieve pain even when tolerance to opioids was present. This mechanism did not produce dependence after treatment and could be explored to develop new drugs.
  • New Celexor Bio to focus on cell depletion of pathologic cells in autoimmune and inflammatory disorders

    Inmagene Biopharmaceuticals Technology (Shanghai) Co. Ltd. and biotech investment firm Aditum Bio Management Company LLC have announced the formation of Celexor Bio, a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene’s IMG-018, a plasmacytoid dendritic cell (pDC)-depleting antibody targeting immunoglobulin-like transcript 7 (ILT7).
  • Epitope editing in hematopoietic cells provides CAR T immunotherapy against all types of blood cancer

    A new method of CAR T-cell immunotherapy developed by researchers at the University of Pennsylvania Perelman School of Medicine could serve as a treatment for most blood cancers. Until now, CAR T-based immunotherapy for hematological malignancies has targeted the antigens CD19 for B cells, CD7 for T cells, BCMA for myeloma, and CD33 for AML.
  • Replay’s Syena and Jura Bio collaborate to advance TCR-NK therapies for cancer

    Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.
  • Seinda Pharmaceutical patents new peptides for ocular conditions

    Seinda Pharmaceutical Corp. has disclosed peptides reported to be useful for the treatment of corneal epithelial defect, corneal neovascularization and dry eye.
  • Holiday notice

    In accordance with the publishing schedule, BioWorld Science will not be published on Monday, Sept. 25, 2023.
  • Other news to note for Sept. 22, 2023

    Additional early-stage research and drug discovery news in brief.
  • Via Nova Therapeutics receives FDA clearance of IND for influenza A nucleoprotein inhibitor

    Via Nova Therapeutics Inc. has received clearance of its IND application from the FDA for its influenza A nucleoprotein inhibitor, VNT-101. The novel investigational small molecule is directed against a novel target, the influenza A nucleoprotein, and is being developed for treatment of seasonal influenza A infection.
  • Honokiol derivative shows potent activity in models of human nasopharyngeal carcinoma

    Researchers from Bengbu Medical College have discovered new derivatives of honokiol, a biphenyl neolignan extracted from Magnolia species, which has been shown to possess pharmacological properties, including anticancer, anti-inflammatory, antioxidant, anti-infectious and neuroprotective activities. A total of 21 new honokiol derivatives were synthesized, with derivative [I] being selected as the lead with the most potent in vitro cytotoxic activity.
  • [177Lu]BQ-7876, a novel PSMA-targeting agent for the treatment of prostate cancer

    3D illustration showing tumor inside prostate gland and closeup view of cancer cells
  • Terns Pharmaceuticals divulges new GLP-1R agonists

  • Novel FAP-targeting radioligand for tumor imaging presented 

  • Krystal’s KB-408 cleared by FDA to enter phase I trial in α1-antitrypsin deficiency

    Liver and lungs
  • Chia Tai Tianqing Pharmaceutical describes new HPK1 inhibitors for cancer

  • Wuhan Zhongcheng Health Bio-Pharm Technology presents new ATR kinase inhibitors

  • Debiopharm and Sunrock sign option and license agreement for ADCs in cancer

    Antibodies attacking cancer cell
  • Westvac Biopharma discovers new Mpro inhibitors for SARS-CoV-2

BioWorld Insider Podcast

Google’s Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near future.

Listen now

Conferences

  • Radiopharmaceutical illustration

    Discovery of novel radiotheragnostic agents with improved tumor-to-background ratios

    New compound
    Researchers from University Hospital Basel and Universitätsklinikum Ulm presented the discovery of novel radiotheragnostic candidates targeting C-X-C chemokine receptor 4 (CXCR4), which is highly expressed in various cancers and has been linked to poor prognosis.
  • [68Ga]NOTA-XH05, a LAG-3-targeting PET imaging agent to monitor immunotherapy response

    New compound
    Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
  • [68Ga]PF-381, a radiolabeled peptide for early detection of CD38-positive lymphomas

    New compound
    The discovery of new 68Ga-labeled CD38-targeted peptides for PET imaging was recently discussed by researchers from Peking University First Hospital and China National Center For Nanoscience & Technology.
  • Lungs

    BTI-615 inhibits TGF-β1 signaling and suppresses lung fibrosis in rats

    New compound
    Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response, and its dysregulation drives the formation of the fibrotic niche, which impairs the capacity of tissue repair, regeneration and homeostasis.
More in Conferences

Today's news in brief

  • Other news to note for Sept. 22, 2023

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • Versitech and Ningbo Combireg Pharmaceutical patent benzothiazole compounds to treat SARS-CoV-2

  • Recludix Pharma presents new STAT3 and STAT6 inhibitors

  • Tegid Therapeutics describes new PROTACS targeting MALT1

  • Astellas and Mitobridge divulge new STING antagonists

  • Roche researchers patent new antibacterials

  • Japan Tobacco presents new HPGDS inhibitors

  • Celros Biotech describes new NOX2 and NOX4 inhibitors

  • Assembly Biosciences divulges new compounds for hepatitis B and D

  • Satyarx Pharma patents new RAD51 inhibitors for cancer

  • Biohaven Therapeutics discovers new KCNQ2/3 activators

Cancer

  • CAR T cell attacking cancer cells

    Leucid Bio gets MHRA go-ahead for phase I/II study of NKG2D CAR T-cell therapy LEU-011

    Regulatory
    Leucid Bio Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to commence a phase I/II trial of LEU-011 for the treatment of adults with relapsed or refractory solid tumors.
  • Orionis Biosciences collaborates with Genentech to discover molecular glues

    Drug design, drug delivery and technologies
  • Novel CDK7 inhibitor SHR-5428 is effective in breast cancer models

  • New HER3-targeting ADC with broader anticancer applications in HER3-expressing tumors

    Antibody-drug conjugate
  • Benevolentai and Merck KGaA enter drug discovery and development collaboration

    Artificial intelligence
More in Cancer
black cortellis ad

Infection

  • Pharmaceutical manufacturing

    Evaxion Biotech collaborates with Afrigen Biologics on mRNA vaccine against gonorrhea

    Collaboration
    Evaxion Biotech A/S has established a collaboration with Afrigen Biologics Pty Ltd. aimed at developing a prophylactic mRNA vaccine against gonorrhea.
  • Gates Foundation investment supports Transimmune’s work on enhancing mRNA vaccines

    Immune
    Transimmune AG has been awarded a $5 million investment from the Bill & Melinda Gates Strategic Investment Fund that will be used to leverage Transimmune’s physiologically induced dendritic cells (phDCs) to enhance the potency of mRNA vaccines in infectious diseases. The initial focus will be on a...
  • Spybiotech seeks clearance in UK to begin clinical testing of SPYVLP-01 for human CMV

    Regulatory
    Spybiotech Ltd. has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP-01, a vaccine targeting human cytomegalovirus (CMV) using its hepatitis B virus-like-particle platform technology.
  • Phaxiam initiates new preclinical phage program targeting K. pneumoniae

  • Novel acylthiourea derivative shows efficacy in broad-spectrum influenza models

  • Evaxion partners to advance new bacterial vaccine program

    Artificial intelligence
  • Novel pleuromutilin derivatives show efficacy in drug-resistant infections

More in Infection

Neurology/Psychiatric

  • Brain as light bulb filament

    Addex consortium awarded grant to advance mGlu2 NAMs for mild neurocognitive disorder

    Grant
    A consortium led by Addex Therapeutics Ltd. has been awarded a €4 million (US$4.3 million) Eurostars grant to support its metabotropic glutamate mGlu2 receptor negative allosteric modulator (NAM) program for mild neurocognitive disorder.
  • Stem cell-derived vertebral bone with recruited breast cancer tumor cells

    The skeletal stem cell contains multitudes, with translational implications

    Cancer
    Long bones, vertebrae and skull bones have distinct types of stem cells, and new insights into those stem cells could lead to new ways to treat both rare developmental disorders of skull formation and the all-too-common phenomenon of bone metastases. Scientifically, the work, which was published in...
  • Viva Star Biosciences divulges new NLRP3 inflammasome inhibitors

    Patents
    Viva Star Biosciences (Suzhou) Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.
  • Concept art for adeno-associated viral-based gene therapy.

    Atamyo files CTA in Europe for ATA-200 gene therapy for limb-girdle muscular dystrophy type 2C/R5

    Regulatory
    Atamyo Therapeutics SAS has filed a clinical trial application (CTA) in Europe for ATA-200, its gene therapy targeting γ-sarcoglycan (SGCG)-related limb-girdle muscular dystrophy type 2C/R5 (LGMD-R5).
  • Amyloid plaque on nerve cell

    Irisin reduces amyloid-β levels in 3D culture models of Alzheimer’s disease

    Irisin is a myokine derived from fibronectin type III domain containing 5 (FNDC5) released into the circulation during physical exercise. It is known that FNDC5/irisin stimulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and also that Alzheimer’s disease (AD) models and...
More in Neurology/Psychiatric

Immune

  • Biontech and CEPI partner to develop mRNA mpox vaccine candidates

  • Sunshine Lake Pharma identifies new TLR8 agonists

  • From membranes to metabolites, looking at lipids

  • Nanomedsyn prepares and tests new IGF-2R-targeting LYTACs

  • Myelin damaged by multiple sclerosis could be repaired by reducing levels of an enzyme

  • Novel antibody Ab-IPL-IL-17 limits disease progression in preclinical models of rheumatoid arthritis

  • The human thymus has multipotent stem cells with the capacity to maintain it

  • CEPI and IVI renew collaboration on vaccines against emerging infectious diseases

  • Novel anti-IL-17A inhibitor shows similar efficacy to biological therapies in IL-17-driven disorders

  • NIH award supports advancement of BITT’s CD40 antagonist antibody BITT-101 for Sjögren’s syndrome

Endocrine/Metabolic

  • Illustration of pancreas and kidney organs

    Kidney disease culprit D2D3 also attacks pancreas

    Nephrology
    The contribution of the soluble form of urokinase-type plasminogen activator receptor (suPAR) as a risk factor for chronic kidney diseases (CKD) is well known. Researchers from Rush University Medical Center, Harvard Medical School and collaborators have now identified D2D3, a suPAR fragment, as...
  • Inversago Pharma divulges new cannabinoid CB1 receptor antagonists

    Patents
  • Biomarin outlines progress of preclinical pipeline

    Drug design, drug delivery and technologies
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    Patents
  • Precision Biosciences outlines pipeline progress

    Drug design, drug delivery and technologies
More in Endocrine/Metabolic
black cortellis ad

Biomarkers

  • DNA double helix with sand hour glass

    Biomarker brainteaser: Aging? Or just changing?

    Conferences
    “Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor. Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the...
  • Biomarker discovery for patients with treatment-resistant ovarian cancer

    Cancer
    Despite continual investment in research focused on high-grade serous ovarian cancer (HGSOC), the 5-year survival rate of ∼30% for most patients has remained unchanged for decades. While ≤20% of HGSOC patients present with treatment-refractory disease, therapeutic strategies have not changed...
  • PARP inhibitors demonstrate efficacy in SF3B1 mutant cancer models

    Cancer
    To identify candidate therapeutic targets for cancers with SF3B1 hotspot mutations, drug-sensitivity screening of an in-house library of 80 small-molecule inhibitors resulted in the identification of a series of candidate SF3B1 mutant (SF3B1[MUT]) synthetic lethal drugs that led to significant...
  • First preliminary evaluation of a genetic test toward prompt diagnosis of bipolar spectrum disorder

    Neurology/Psychiatric
  • Researchers find link between glycolysis biomarkers and Alzheimer’s disease

    Conferences
  • MTBR-tau243 as a specific cerebrospinal fluid biomarker of tau aggregate pathology

    Neurology/Psychiatric
  • INDYGON syndrome, a novel spliceosomopathy caused by biallelic variants in SART3

    Conferences
More in Biomarkers

Gastrointestinal

  • Genflow receives recommendation from Belgium’s FAHMP regarding trials with GF-1002 in NASH

    Regulatory
    Genflow Biosciences plc has received correspondence from Belgium’s Federal Agency for Medicines and Health Products (FAHMP) with a recommendation to initiate a phase I/II trial of GF-1002 in patients with nonalcoholic steatohepatitis (NASH),...
  • Hepagene’s THR-β agonist HPG-7233 cleared to enter clinic for NASH and dyslipidemia

    Regulatory
    Hepagene Therapeutics Inc. has received FDA clearance of its IND application for HPG-7233 for the treatment of patients with nonalcoholic steatohepatitis (NASH) and dyslipidemia.
  • Therapyx’s Fapxil awarded US orphan drug designation for familial adenomatous polyposis

    Regulatory
    Therapyx Inc.’s Fapxil has been awarded orphan drug designation by the FDA for the treatment of familial adenomatous polyposis (FAP).
  • Unconventional intestinal epithelial cells are influential in inflammatory bowel disease control and prevention

    In the gastrointestinal tract, intraepithelial lymphocytes are tasked with protecting the epithelium against pathogens and participating in wound repair and correct mucosal barrier functioning. In a study published in the Sept. 15, 2023, issue of ...
  • Palisade Bio licenses rights to Giiant’s prodrug platform and candidates for inflammatory bowel disease

    License
    Palisade Bio Inc. has entered into a licensing agreement with Giiant Pharma Inc. that provides...
  • Nexys Therapeutics describes new AhR agonists

    Patents
    Nexys Therapeutics Inc. has identified aryl hydrocarbon receptor (AhR) agonists and their prodrugs reported to be useful for the treatment of inflammatory bowel disease, multiple sclerosis and Huntington’s disease.
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • AI: driving drug development from effective to remarkable
  • The struggle is real: The first half of 2023 was an uphill climb
  • The biosimilars challenge to Humira revs up
  • Preventing opioid overdoses with a smart patch
  • Better times ahead for the biopharma sector? Could be, the new numbers say
  • Radiopharmaceuticals: The next big disrupter?
  • Cambrian carves out a new niche as it works to keep people from getting sick
  • Rethinking obesity: Fitness may be more directly linked to health than weight
  • Looking ahead to 2023: CEOs contemplate the new normal
  • $1B+ biopharma deals keep values afloat, even amid muted volume

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing